Author:
Bang Y.-J,Ruiz E.Yañez,Van Cutsem E.,Lee K.-W,Wyrwicz L.,Schenker M.,Alsina M.,Ryu M.-H,Chung H.-C,Evesque L.,Al-Batran S.-E,Park S.H.,Lichinitser M.,Boku N.,Moehler M.H.,Hong J.,Xiong H.,Hallwachs R.,Conti I.,Taieb J.
Funder
Merck KGaA
Merck KGaA and Pfizer Inc.
ClinicalThinking, Inc.
Pfizer Inc
Reference24 articles.
1. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Kang;Lancet,2017
2. Chemotherapy for advanced gastric cancer;Wagner;Cochrane Database Syst Rev,2017
3. Advanced gastric cancer: current treatment landscape and future perspectives;Digklia;WJG,2016
4. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Smyth;Ann Oncol,2016
Cited by
422 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献